Dr. Lily Chu The results of this survey were presented by Lily Chu at the FDA Drug Development Workshop for CFS and ME on April 25-26, 2013.
Preliminary Results – April 2013 FDA Workshop Survey
By Lily Chu, Leonard Jason, Madison Sunnquist, Suzanna So
Demographics:
85% of our subjects were female and almost all subjects were Caucasian. The average age was 51 and the average duration of illness was 18 years. For 50% of our respondents, this survey is the only way they are participating in this workshop.
Symptoms:
The 5 most significant symptoms were fatigue, post-exertional malaise, pain, sleep, and cognitive problems. Symptoms that haven’t been studied as much such as multiple chemical sensitivities, gastrointestinal symptoms, and orthostatic intolerance were also deemed to be significant by over 50% of our subjects. 99% felt that their illness was not improving over time, citing worsening of existing symptoms and appearance of new symptoms.
Out of five objective tests we asked about, 66% had at least one abnormal result. For natural killer cell activity, for example, 70% noted an abnormal result. Tests like these could be used as study inclusion criteria, as outcome measures, and as a way to select subgroups for analysis. We believe that studying subgroups may help yield more effective treatments given the heterogenous nature of CFS.
Impact on Daily Life:
Using a standardized measure of physical functioning, we found our respondents to be more disabled than 95% of the general US population. Only 13% were employed, with almost all citing ME and or CFS as the reason for why they could not work. For even basic personal care, 89% needed assistance or had to change their pre-illness routine. On their worst days, 60% were bedridden. On their best days, 75% could only do some light housework or less.
Perspectives on Current Treatment:
75% of people felt current treatments were not helpful or only slightly helpful but not enough to improve their day-to-day function. Patients repeatedly wrote about the need for disease-modifying treatments and not only for treatments that helped control symptoms.
We asked about how well currently recommended treatments worked for the illness overall and for three common symptoms: sleep, pain, and cognitive problems.
These treatments were cited as helpful by more than 50% of subjects:
The main reasons cited for stopping a medicine were side effects followed by decrease in effectiveness over time, especially with sleep medications. For effective non-drug treatments, cost and insurance coverage were major reasons for discontinuation. Respondents were also concerned about being more sensitive to drugs and the dependency potential of some medications.
Limitations:
The overwhelming majority of respondents to our survey self-identified as Caucasian. This is likely a result of adequate access to care to obtain an accurate diagnosis, Internet access, and membership in support groups rather than an accurate reflection of the epidemiology of ME or CFS. In fact, multiple community-based studies suggest a higher prevalence and more severe morbidity in minority populations.
We did ask about antibiotics, antivirals, and immunomodulators but 1) answers were rather mixed (side effects, not enough time on medicine due to physician/ cost, etc.) 2) sample sizes were too small to come to concrete conclusions. Also, to date, no blockbuster drug has been noted in open patient comments to be very successful by more than a handful of respondents. In addition given the relatively short length/ nature of the survey, we weren't able to subgroup respondents and ask how they did on various treatments, which I think is key to finding effective treatments.
For more information, contact Lily Chu ([email protected])
Preliminary Results – April 2013 FDA Workshop Survey
By Lily Chu, Leonard Jason, Madison Sunnquist, Suzanna So
Demographics:
85% of our subjects were female and almost all subjects were Caucasian. The average age was 51 and the average duration of illness was 18 years. For 50% of our respondents, this survey is the only way they are participating in this workshop.
Symptoms:
The 5 most significant symptoms were fatigue, post-exertional malaise, pain, sleep, and cognitive problems. Symptoms that haven’t been studied as much such as multiple chemical sensitivities, gastrointestinal symptoms, and orthostatic intolerance were also deemed to be significant by over 50% of our subjects. 99% felt that their illness was not improving over time, citing worsening of existing symptoms and appearance of new symptoms.
Out of five objective tests we asked about, 66% had at least one abnormal result. For natural killer cell activity, for example, 70% noted an abnormal result. Tests like these could be used as study inclusion criteria, as outcome measures, and as a way to select subgroups for analysis. We believe that studying subgroups may help yield more effective treatments given the heterogenous nature of CFS.
Impact on Daily Life:
Using a standardized measure of physical functioning, we found our respondents to be more disabled than 95% of the general US population. Only 13% were employed, with almost all citing ME and or CFS as the reason for why they could not work. For even basic personal care, 89% needed assistance or had to change their pre-illness routine. On their worst days, 60% were bedridden. On their best days, 75% could only do some light housework or less.
Perspectives on Current Treatment:
75% of people felt current treatments were not helpful or only slightly helpful but not enough to improve their day-to-day function. Patients repeatedly wrote about the need for disease-modifying treatments and not only for treatments that helped control symptoms.
We asked about how well currently recommended treatments worked for the illness overall and for three common symptoms: sleep, pain, and cognitive problems.
These treatments were cited as helpful by more than 50% of subjects:
- for the overall illness - balancing rest with activity, restricting or modifying physical/ mental activities
- for sleep – CPAP, over-the-counter medicines, zolpidem, eszoplicone, TCAs, trazodone, benzodiazepines
- for pain – short/ long-acting opioids, flexeril, ibuprofen
The main reasons cited for stopping a medicine were side effects followed by decrease in effectiveness over time, especially with sleep medications. For effective non-drug treatments, cost and insurance coverage were major reasons for discontinuation. Respondents were also concerned about being more sensitive to drugs and the dependency potential of some medications.
Limitations:
The overwhelming majority of respondents to our survey self-identified as Caucasian. This is likely a result of adequate access to care to obtain an accurate diagnosis, Internet access, and membership in support groups rather than an accurate reflection of the epidemiology of ME or CFS. In fact, multiple community-based studies suggest a higher prevalence and more severe morbidity in minority populations.
We did ask about antibiotics, antivirals, and immunomodulators but 1) answers were rather mixed (side effects, not enough time on medicine due to physician/ cost, etc.) 2) sample sizes were too small to come to concrete conclusions. Also, to date, no blockbuster drug has been noted in open patient comments to be very successful by more than a handful of respondents. In addition given the relatively short length/ nature of the survey, we weren't able to subgroup respondents and ask how they did on various treatments, which I think is key to finding effective treatments.
For more information, contact Lily Chu ([email protected])
RSS Feed
